Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy.
Tokita, K
Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. [electronic resource] - Leukemia Jan 2007 - 190-2 p. digital
Publication Type: Case Reports; Letter
0887-6924
10.1038/sj.leu.2404397 doi
Adult
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Benzamides
Chromosomes, Human, Pair 12
Chromosomes, Human, Pair 5
Chronic Disease
Fatal Outcome
Humans
Imatinib Mesylate
Leukemia, Myeloid, Acute--drug therapy
Male
Oncogene Proteins, Fusion--biosynthesis
Piperazines--therapeutic use
Primary Myelofibrosis--complications
Pyrimidines--therapeutic use
Transcription, Genetic
Translocation, Genetic
Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. [electronic resource] - Leukemia Jan 2007 - 190-2 p. digital
Publication Type: Case Reports; Letter
0887-6924
10.1038/sj.leu.2404397 doi
Adult
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Benzamides
Chromosomes, Human, Pair 12
Chromosomes, Human, Pair 5
Chronic Disease
Fatal Outcome
Humans
Imatinib Mesylate
Leukemia, Myeloid, Acute--drug therapy
Male
Oncogene Proteins, Fusion--biosynthesis
Piperazines--therapeutic use
Primary Myelofibrosis--complications
Pyrimidines--therapeutic use
Transcription, Genetic
Translocation, Genetic